Innate inflammation in type 1 diabetes

详细信息    查看全文

• 作者：Susanne M. Cabrera^a ; ^b ; Angela M. Henschel^a ; ^b ; Martin J. Hessner^a ; ^b ; ^{mhessner@mcw.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：AAs ; autoantibodies ; AAT ; alpha-1 antitrypsin ; BB ; biobreeding rat strain ; BBDP ; biobreeding diabetes prone ; BBDR ; biobreeding diabetes resistant ; ELISA ; enzyme-linked immunosorbent assay ; GI ; gastrointestinal ; HLA ; human leukocyte antigen ; HRS ; high-risk sibling (healthy ; autoantibody negative ; and possess DR3 and/or DR4 haplotype) ; IFN-α ; interferon gamma ; IL-1 ; interleukin 1 ; IL-10 ; interleukin 10 ; IL-1RN ; interleukin 1 receptor antagonist ; KRV ; Kilham's rat virus ; LRS ; low-risk sibling (heal
• 刊名：Translational Research
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：167
• 期：1
• 页码：214-227
• 全文大小：1388 K

文摘

Type 1 diabetes mellitus (T1D) is an autoimmune disease often diagnosed in childhood that results in pancreatic β-cell destruction and life-long insulin dependence. T1D susceptibility involves a complex interplay between genetic and environmental factors and has historically been attributed to adaptive immunity, although there is now increasing evidence for a role of innate inflammation. Here, we review studies that define a heightened age-dependent innate inflammatory state in T1D families that is paralleled with high fidelity by the T1D-susceptible biobreeding rat. Innate inflammation may be driven by changes in interactions between the host and environment, such as through an altered microbiome, intestinal hyperpermeability, or viral exposures. Special focus is put on the temporal measurement of plasma-induced transcriptional signatures of recent-onset T1D patients and their siblings as well as in the biobreeding rat as it defines the natural history of innate inflammation. These sensitive and comprehensive analyses have also revealed that those who successfully managed T1D risk develop an age-dependent immunoregulatory state, providing a possible mechanism for the juvenile nature of T1D. Therapeutic targeting of innate inflammation has been proven effective in preventing and delaying T1D in rat models. Clinical trials of agents that suppress innate inflammation have had more modest success, but efficacy may be improved by the addition of combinatorial approaches that target other aspects of T1D pathogenesis. An understanding of innate inflammation and mechanisms by which this susceptibility is both potentiated and mitigated offers important insight into T1D progression and avenues for therapeutic intervention.